MAM
AUPH icon

Melqart Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Melqart Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-916,321
Closed -$21M – 72
2021
Q4 		$21M Buy
+916,321
New +$21.7M 1.06% 26

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Melqart Asset Management's AUPH Position: Q1 2022 in Review

Melqart Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 916,321 shares — an estimated $21M sold.

Melqart Asset Management first reported a position in AUPH in Q4 2021 and held it in 1 quarter. The position peaked at $21M in Q4 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • Melqart Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Melqart Asset Management sold 916,321 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $21M.
  • Melqart Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Melqart Asset Management's Aurinia Pharmaceuticals position peaked at $21M in Q4 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Melqart Asset Management's 13F filing for Q1 2022, filed 16 May 2022.